Bruker Corporation · NASDAQ:BRKR

Bruker — Cowen and Company 37th Annual Health Care Conference 2017

13 slides from Bruker's conference presentation, Mar 6, 2017

  1. Slide 1: Bruker drives profitable growth and margin expansion

    Bruker drives profitable growth and margin expansion by enabling scientific discoveries and by delivering high- performance analytical, life science and diagnostic solutions © Bruker Corporation Innovation with Integrity

  2. Slide 2: Safe Harbor Statement

    Bruker Corporation Safe Harbor Statement Any statements contained in this presentation that do not describe historical facts may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based on current expectati

  3. Slide 3: 2017 Key Messages & Financial Objectives

    2017 Key Messages & Financial Objectives 1. Bruker is a differentiated leader in attractive markets for analytical, life science and diagnostic tools, and our brand stands for innovation:  Market leader in unique, high value technologies: NMR, MALDI-TOF, MALDI BioTyper, FTMS, AFM, XRD & Superconduc

  4. Slide 4: Bruker Overview: Three Primary Life-Science Tools Groups with Global Footprint

    Three Primary Life-Science Tools Bruker Overview Groups with Global Footprint • Founded in 1960 Revenue breakdown (FY 2016): BioSpin Systems • FY2016 revenue: ~$1.6 billion 35% • R&D investment: ~9% of revenue 75% CALID • ~75% of revenue from scientific and diagnostic instruments BEST 8% 29% 25% • ~

  5. Slide 5: Technology Portfolio & Key Markets

    Bruker Technology Portfolio & Key Markets Differentiated, high-performance scientific instruments, Enabling research and analysis analytical tools and diagnostic solutions of life and materials at: Preclinical Nuclear Magnetic Imaging Resonance (NMR) Microscopic & Nano-Scales Mass Microbiology Spect

  6. Slide 6: Bruker Scientific Instruments (BSI) Segment

    Bruker Scientific Instruments (BSI) Segment Three Life Science Tools & Diagnostics (LST & DX) Groups: BioSpin Group CALID Group NANO Group ~$563M FY2016 revenue ~$475M FY2016 revenue ~$455M FY 2016 revenue • NMR/EPR for Life-Science Research & Pharma • Mass Spectrometry for • Atomic Force Microscopy

  7. Slide 7: Energy & Supercon Technologies (BEST) Segment

    Bruker Energy & Supercon Technologies (BEST) Segment In Nov. 2016, BEST acquired OST for $17.5M Becoming a Global Leader in Superconductors Standalone BEST in 2016(1): ~$124M in revenue Standalone OST in 2016E(2): ~$50M in revenue  Supplier of superconductors and physics technologies for  Supplier

  8. Slide 8: 2016-2018: From Transformation to Operational Excellence

    Bruker 2016-2018 From Transformation to Operational Excellence: 2013 2014 2015 2016 2017 2018 Outsourcing Bruker BioSpin Rightsizing Operational Excellence Outsourcing Bruker NANO • Lean manufacturing Rightsizing & Footprint Consolidation • Continued outsourcing Outsourcing • Better business process

  9. Slide 9: Financial Overview

    Bruker Financial Overview Despite end market and FX headwinds, Bruker is delivering strong margin expansion and EPS growth Reported Revenue Non-GAAP Operating Margin In $m ~460 bps of Non-GAAP Operating Margin expansion over 2 years (1.7%) 1.2 2000 +0.0% 14.8% (10.2%) (0.8%) 15.0% 13.3% 1 (2.0%) 150

  10. Slide 10: FY 2016 financials

    Bruker FY 2016 financials Continued strong margin expansion and profitability improvements Non-GAAP Non-GAAP Non-GAAP EBITDA Non-GAAP Gross Margin Operating Margin EPS 48.1% 14.8% $290M 46.2% 13.3% $258M $1.19 $0.89 +190 bps +150 bps +$32M +34% FY 2015 FY 2016 * Non-GAAP gross margin, non-GAAP opera

  11. Slide 11: Working Capital Efficiency & Disciplined Capital Allocation

    Working Capital Efficiency & Disciplined Capital Allocation $1,400 0.60 SHARE BUYBACK PROGRAM $1,200 • BRKR share repurchase of $225M 0.46 authorized in November 2015 was $1,000 completed in December 2016 0.37 0.40 $832m $800 QUARTERLY DIVIDEND $598 $600 • Bruker pays a quarterly dividend of 0.20 $0

  12. Slide 12: FY 2017 Guidance: Return to organic revenue growth, continue operating margin expansion

    FY 2017 Guidance: Return to organic revenue growth, continue operating margin expansion(1) FY 2017 Guidance 2017 ASSUMPTIONS  Organic revenue growth: +1% to +2% Revenue Growth y-o-y +1.5% to +2.5%  Acquisition revenue growth: +3.5% to +4% Non-GAAP Operating Margin +40 bps to +70 bps  FX revenue h

  13. Slide 13: www.bruker.com

    www.bruker.com © Bruker Corporation

Bruker — Cowen and Company 37th Annual Health Care Conference 2017 on 6ix